

**AMENDMENTS TO THE CLAIMS**

1. (Withdrawn – Previously Presented) A method of producing a discrete film dosage, comprising:
  - a) forming a non-gelatin polymeric film without active ingredients incorporated therein;
  - b) applying a polar liquid carrier to one or more surfaces of the film, the polar liquid carrier incorporating at least one active ingredient; and
  - c) allowing the applied polar liquid carrier to associate and cure with the film, to result in the complete absorption of the at least one active ingredient within the film forming a polymer film product.
2. (Withdrawn) A method according to claim 1, wherein the non-gelatin film produced comprises one or more layers which associate with one another to a lesser or greater degree to form a partially or wholly polymerically homogeneous film.
3. (Withdrawn) A method according to claim 1, wherein the polymeric mass of the film or films is increased marginally or substantially after steps b) or c).
4. (Cancelled)
5. (Withdrawn) A method according to claim 1 whereby one or more polymeric substances are also deposited on the film surface.

6. (Withdrawn – Previously Presented) A method according to claim 1, wherein the at least one active ingredient in the polar liquid carrier is transported into the film during step c) of claim 1.

7. (Withdrawn – Previously Presented) A method according to claim 2 wherein the at least one active ingredient is selectively transported.

8. (Withdrawn) A method according to claim 1, wherein the non-gelatin film comprises a cellulose ether film.

9. (Withdrawn – Previously Presented) A method according to claim 1, wherein the non-gelatin film comprises one or more of the following polymers:

hydroxypropyl methylcellulose (HPMC),

hydroxy propyl cellulose (HPC),

hydroxy ethyl methyl cellulose (HEMC),

hydroxy ethyl cellulose (HEC),

methyl cellulose (MC),

carboxy methylcellulose (CMC),

ethyl cellulose (EC),

sodium carboxy methylcellulose

and salts and derivatives of all aforesaid.

10. (Withdrawn – Previously Presented) A method according to claim 1, wherein the polar liquid carrier comprises a same or similar polymeric material as to which forms the non-gelatin film.

11. (Withdrawn – Previously Presented) A method according to claim 1, wherein the polar liquid carrier comprises a material which is chemically or physically compatible with the material which forms the non-gelatin film.

12. (Withdrawn – Previously Presented) A method according to claim 1, wherein the at least one active ingredient is transported from the polar liquid carrier into the film.

13. (Withdrawn – Previously Presented) A method according to claim 1, wherein the at least one active ingredient has a higher affinity for the polar liquid carrier than the film.

14. (Withdrawn – Previously Presented) A method according to claim 1, wherein the at least one active ingredient has a higher affinity for the film than the polar liquid carrier.

15. (Withdrawn – Previously Presented) A method according to claim 1, wherein the polar liquid carrier incorporates 2 or more active ingredients having the same or differing affinities for the film and the polar liquid carrier.

16. (Currently Amended) A discrete single layer cured film dosage to be taken orally, internally, or epidermally and having a concentration gradient of at least one active ingredient, the film dosage being produced by the method of:

- a) forming a non-gelatin polymeric film with or without active ingredients incorporated therein;
- b) applying a polar liquid carrier to one ~~or more surfaces~~ surface of the polymeric film, the polar liquid carrier incorporating the at least one active ingredient; and
- c) allowing the applied polar liquid carrier to associate and cure with the polymeric film, to result in the complete absorption of the at least one active ingredient within the polymeric film ~~forming a polymer film product, and resulting in~~ formation of a single layer cured film dosage having a concentration gradient within the film dosage, from a first concentration of the active ingredient at a first side of the film dosage, to a second concentration of the active ingredient at a second side of the film dosage, the second side being opposite the first side, and the first concentration being greater than the second concentration.

17-20. (Cancelled)

21. (Currently Amended) A discrete single layer cured film dosage according to claim 16, wherein the polymer film product is coiled.

22. (Currently Amended) A discrete single layer cured film dosage according to claim 16, wherein the polymer film product is folded in a zig-zag formation.

23-24. (Cancelled)

25. (Currently Amended) A discrete single layer cured film dosage according to claim 16, wherein the polymer film product is packaged to form a dose unit.

26. (Currently Amended) A discrete single layer cured film dosage according to claim 16, wherein the polar liquid carrier is applied to the film to form a pattern.

27. (Cancelled)

28. (Currently Amended) A pharmaceutical dosage form derived from a discrete single layer cured film dosage according to claim 16.

29. (Withdrawn – Previously Presented) Use of a discrete film dosage according to claim 16, wherein the polymer film product is placed on the tongue of a human or animal and the at least one active ingredient is released in a convenient manner as the polymer film product disintegrates.

30. (Currently Amended) A tablet, powder slug or capsule made from or coated, enrobed or encapsulated with a discrete single layer cured film dosage according to claim 16.

31-35. (Cancelled)

36. (Withdrawn – Previously Presented) A method according to claim 10, wherein the polar liquid carrier comprises a material which is chemically or physically compatible with the material which forms the non-gelatin film, and wherein 2 or more active ingredients have the same or differing affinities for the film and liquid.

37-42. (Cancelled)

43. (Currently Amended) A discrete single layer cured film dosage according to claim 16, wherein the polar liquid carrier is cured at room temperature.

44. (Currently Amended) A discrete single layer cured film dosage according to claim 16, wherein the polar liquid carrier is cured through application of heat to a temperature below the boiling point of the polar liquid carrier.

45. (Currently Amended) A discrete single layer cured film dosage according to claim 16, wherein the mass of the film is increased after steps b) and c).

46. (Currently Amended) A discrete single layer cured film dosage according to claim 16, wherein the non-gelatin polymeric film comprises a cellulose ether film.

47. (Currently Amended) A discrete single layer cured film dosage according to claim 16, wherein the non-gelatin polymeric film comprises one or more of the following polymers:

hydroxypropyl methylcellulose (HPMC),  
hydroxy propyl cellulose (HPC),  
hydroxy ethyl methyl cellulose (HEMC),  
hydroxy ethyl cellulose (HEC),  
methyl cellulose (MC),  
carboxy methylcellulose (CMC),  
ethyl cellulose (EC),  
sodium carboxy methylcellulose,  
and salts and derivatives of all aforesaid.

48. (Currently Amended) A discrete single layer cured film dosage according to claim 16, wherein the polymer film product is edible.

49. (Currently Amended) A discrete single layer cured film dosage according to claim 16, wherein the polymer film product is muco-adhesive.

50. (Currently Amended) A discrete single layer cured film dosage according to claim 16, wherein the polymer film product is a medical device.

51. (Currently Amended) A discrete single layer cured film dosage according to claim 16, wherein the at least one active ingredient incorporated in the polar liquid carrier has at least one of a therapeutic effect, an organoleptic effect, a cosmetic effect, and a pharmaceutical effect.

52. (Currently Amended) A discrete single layer cured film dosage according to claim 16, wherein the at least one active ingredient incorporated in the polar liquid carrier is a pharmaceutical compound.

53. (Cancelled)

54. (Currently Amended) A discrete single layer cured film dosage according to claim 16, wherein the at least one active ingredient has a concentration gradient associated with one or more patterns within the polymer film product.

55. (Currently Amended) A discrete single layer cured film dosage according to claim 16, wherein the polymer film product is can be applied mucosally, orally, or topically.